Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis - why cardiovascular risk factors do not equate to overt risk
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tofacitinib (TOFA) shows high retention and a good safety profile in rheumatoid arthritis (RA) patients, even those with cardiovascular risks. Ineffectiveness was the main reason for stopping treatment.
Area Of Science
- Rheumatology
- Pharmacology
- Clinical Medicine
Background
- Rheumatoid arthritis (RA) management requires effective treatments with favorable safety profiles.
- Tofacitinib (TOFA) is a Janus kinase inhibitor used for RA.
- Assessing real-world effectiveness and safety is crucial for treatment optimization.
Purpose Of The Study
- To evaluate the effectiveness and safety of tofacitinib (TOFA) in a real-world rheumatoid arthritis (RA) cohort.
- To determine drug retention rates and reasons for discontinuation.
- To assess the impact of cardiovascular risk factors on TOFA treatment outcomes.
Main Methods
- Retrospective, multicenter cohort study of 209 RA patients treated with TOFA.
- Data collected from electronic registries, chart reviews, and ambulatory care records.
- Analysis of drug retention, discontinuation reasons, adverse events, and cardiovascular risk factors.
Main Results
- High TOFA retention rates observed: 89.3% at 6 months, 82.4% at 12 months, 60.4% at 24 months.
- Ineffectiveness was the primary reason for discontinuation (n=50).
- Low rate of adverse events (AEs); lipid abnormalities, blood count alterations, and infections were common. No major adverse cardiovascular events reported. Multiple cardiovascular risk factors were associated with lower retention and effectiveness.
Conclusions
- Tofacitinib demonstrates high retention and a favorable safety profile in RA patients, including those with cardiovascular risk factors.
- TOFA can be a valuable treatment option for RA, especially with individualized cardiovascular risk management.
- Further research is needed to explore long-term effects and cardiovascular impact in larger populations.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...